Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma.
HDAC isozymes
HDAC6 inhibitors
combinatorial therapies
extracellular vesicles
primary and metastatic uveal melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
received:
18
06
2022
revised:
26
07
2022
accepted:
01
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Patients diagnosed with metastatic uveal melanoma (MUM) have a poor survival prognosis. Unfortunately for this rare disease, there is no known cure and suitable therapeutic options are limited. HDAC6 inhibitors (HDAC6i) are currently in clinical trials for other cancers and show potential beneficial effects against tumor cell survival in vitro and in vivo. In MUM cells, HDAC6i show an anti-proliferative effect in vitro and in preclinical xenograft models. The use of HDAC6 inhibitors as a treatment option for MUM should be explored further. Therefore, this review discusses (1) what is known about HDAC6i in MUM and (2) whether HDAC6 inhibitors offer a potential therapeutic option for MUM.
Identifiants
pubmed: 36012642
pii: ijms23169378
doi: 10.3390/ijms23169378
pmc: PMC9409113
pii:
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Histone Deacetylase 6
EC 3.5.1.98
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Irish Research Council-Enterprise Partnership Scheme 2020 Postdoctoral Fellowship
ID : EPSPD/2020/29
Organisme : TopMed10-Marie Skłodowska-Curie Actions COFUND Programme
ID : 666010
Organisme : CRYSTAL3-European Union's Horizon 2020 Research and Innovation programme
ID : 101007931
Références
Fac Rev. 2021 May 28;10:51
pubmed: 34195690
Cancer Biol Ther. 2015;16(9):1387-96
pubmed: 25951497
Eur J Med Chem. 2020 Oct 1;203:112628
pubmed: 32679451
J Nanobiotechnology. 2021 Nov 17;19(1):364
pubmed: 34789273
Clin Cancer Res. 2004 Oct 15;10(20):6962-8
pubmed: 15501975
Cancers (Basel). 2020 Dec 09;12(12):
pubmed: 33316946
Oncoimmunology. 2022 Feb 22;11(1):2042065
pubmed: 35223194
Clin Cancer Res. 2019 Sep 15;25(18):5686-5701
pubmed: 31227503
Front Genet. 2020 Sep 11;11:578011
pubmed: 33024443
Cancers (Basel). 2021 Jul 02;13(13):
pubmed: 34283046
J Extracell Vesicles. 2021 Dec;10(14):e12144
pubmed: 34919343
Int J Mol Sci. 2020 Nov 02;21(21):
pubmed: 33147762
Oncol Rep. 2022 Feb;47(2):
pubmed: 34958116
Invest New Drugs. 2014 Jun;32(3):526-34
pubmed: 24464266
Int J Oncol. 2022 May;60(5):
pubmed: 35348191
Am J Pathol. 2000 Dec;157(6):1795-801
pubmed: 11106551
Pharmacol Res. 2021 Jan;163:105274
pubmed: 33171304
J Exp Clin Cancer Res. 2021 May 4;40(1):154
pubmed: 33947438
Transl Oncol. 2022 Jun;20:101408
pubmed: 35364557
Front Oncol. 2021 Aug 17;11:718589
pubmed: 34485153
Anticancer Res. 2022 Jan;42(1):471-482
pubmed: 34969757
J Neurochem. 2020 Jan;152(2):221-234
pubmed: 31390677
Cancer Discov. 2017 Aug;7(8):852-867
pubmed: 28408401
J Clin Oncol. 2005 Jun 10;23(17):3912-22
pubmed: 15851766
Bioorg Chem. 2021 Apr;109:104754
pubmed: 33677416
Onco Targets Ther. 2017 Oct 24;10:5129-5136
pubmed: 29123411
Lab Invest. 2017 Jun;97(6):649-656
pubmed: 28263292
Epigenomics. 2016 Mar;8(3):415-28
pubmed: 26950532
Nat Rev Clin Oncol. 2021 Dec;18(12):747
pubmed: 34625736
Eur J Cancer. 2018 Nov;103:41-51
pubmed: 30205280
Pharmacol Res. 2021 Sep;171:105787
pubmed: 34314859
Int J Cancer. 2019 Aug 1;145(3):735-747
pubmed: 30694564
Onco Targets Ther. 2019 Apr 02;12:2409-2419
pubmed: 31118659
Front Pharmacol. 2022 May 16;13:907981
pubmed: 35652048
J Clin Oncol. 2005 Jun 10;23(17):3923-31
pubmed: 15897550
Mol Oncol. 2015 Aug;9(7):1447-1457
pubmed: 25957812
Int J Mol Sci. 2022 May 26;23(11):
pubmed: 35682684
J Biomed Biotechnol. 2011;2011:875824
pubmed: 21076528
Cancer Manag Res. 2018 Nov 08;10:5451-5460
pubmed: 30519093
Int J Mol Sci. 2018 Aug 09;19(8):
pubmed: 30096875
Oncotarget. 2017 Dec 15;9(5):6174-6187
pubmed: 29464063
Cancers (Basel). 2020 Sep 08;12(9):
pubmed: 32911759
Oncol Rep. 2017 Feb;37(2):1270-1276
pubmed: 28035401
Trends Mol Med. 2006 Sep;12(9):406-14
pubmed: 16899407
Clin Cancer Res. 2012 Aug 15;18(16):4345-55
pubmed: 22733540
Front Pharmacol. 2021 Oct 01;12:741697
pubmed: 34658878
EMBO Rep. 2020 Sep 3;21(9):e50863
pubmed: 32754983
Oxid Med Cell Longev. 2021 Dec 11;2021:9911537
pubmed: 34931134
Nat Commun. 2021 Aug 27;12(1):5155
pubmed: 34453044
BMC Cancer. 2019 May 2;19(1):415
pubmed: 31046743
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
FEBS J. 2021 Nov;288(21):6226-6249
pubmed: 33838075
Cell Death Dis. 2018 Jul 26;9(8):817
pubmed: 30050135
Cancers (Basel). 2021 Sep 23;13(19):
pubmed: 34638249
Sci Transl Med. 2019 Sep 11;11(509):
pubmed: 31511426
Front Oncol. 2019 Nov 05;9:1145
pubmed: 31750244
Oncotarget. 2013 Dec;4(12):2225-36
pubmed: 24163230
Crit Rev Oncol Hematol. 2022 Apr;172:103652
pubmed: 35304261
J Biol Chem. 2018 Feb 9;293(6):1976-1993
pubmed: 29259132
Anticancer Res. 2018 Jul;38(7):3817-3824
pubmed: 29970501
BMC Cancer. 2014 Dec 16;14:962
pubmed: 25510783
Oncol Rep. 2016 Jul;36(1):589-97
pubmed: 27221381
J Cell Biochem. 2017 Dec;118(12):4414-4424
pubmed: 28452069
Cancers (Basel). 2020 Sep 25;12(10):
pubmed: 32992823
Front Cell Dev Biol. 2021 Dec 02;9:719390
pubmed: 34938729
J Enzyme Inhib Med Chem. 2021 Dec;36(1):34-47
pubmed: 33100043
Eye (Lond). 2013 Feb;27(2):230-42
pubmed: 23222563
Exp Ther Med. 2021 Dec;22(6):1428
pubmed: 34707709
Front Pharmacol. 2021 Oct 29;12:658197
pubmed: 34776939
Front Oncol. 2021 Sep 06;11:696512
pubmed: 34552864
ChemMedChem. 2011 Jul 4;6(7):1193-8
pubmed: 21416613
Protein Cell. 2014 Mar;5(3):214-23
pubmed: 24474193
Cancers (Basel). 2020 Oct 11;12(10):
pubmed: 33050649
Clin Sci (Lond). 2016 Jun 1;130(12):987-1003
pubmed: 27154743
Cancer Lett. 2017 Aug 1;400:47-60
pubmed: 28455241
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Curr Protoc. 2021 Apr;1(4):e110
pubmed: 33882197
Oncologist. 2021 Mar;26(3):184-e366
pubmed: 33458921
Oncol Lett. 2021 Mar;21(3):201
pubmed: 33574940
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Molecules. 2018 Feb 02;23(2):
pubmed: 29393896
Br J Cancer. 2005 Jun 6;92(11):2032-8
pubmed: 15928660
Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852
pubmed: 33149769
Ann Transl Med. 2021 Apr;9(8):735
pubmed: 33987433
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344957
Drugs. 2022 Apr;82(6):703-710
pubmed: 35364798
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Mol Cancer Ther. 2014 May;13(5):1044-53
pubmed: 24563540
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9
pubmed: 19661225
Oncogene. 2007 Aug 13;26(37):5468-76
pubmed: 17694087
Transl Oncol. 2022 Feb;16:101312
pubmed: 34922087
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Sci Rep. 2019 Apr 16;9(1):6136
pubmed: 30992475
J Innate Immun. 2012;4(5-6):454-62
pubmed: 22302072
Cancer Lett. 2017 Apr 10;391:162-171
pubmed: 28153791
J Skin Cancer. 2011;2011:730170
pubmed: 22046555
Br J Cancer. 2022 Jun;126(11):1511-1528
pubmed: 35190695
PLoS One. 2013 Sep 04;8(9):e73401
pubmed: 24023871
Front Cell Dev Biol. 2020 Sep 29;8:576946
pubmed: 33117804
Anticancer Res. 2021 Mar;41(3):1647-1654
pubmed: 33788761
Oncol Lett. 2021 Jan;21(1):9
pubmed: 33240415
Melanoma Res. 2014 Dec;24(6):525-34
pubmed: 25304237
Molecules. 2022 Jan 21;27(3):
pubmed: 35163980
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
Appl Clin Genet. 2016 Sep 06;9:147-55
pubmed: 27660484
FEBS J. 2013 Feb;280(3):775-93
pubmed: 23181831
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322608
Cancers (Basel). 2022 Feb 20;14(4):
pubmed: 35205815
J Hematol Oncol. 2018 Sep 3;11(1):111
pubmed: 30176876
Mol Oncol. 2021 Dec;15(12):3280-3298
pubmed: 33773029
Ocul Oncol Pathol. 2019 Apr;5(3):153-161
pubmed: 31049320
Cell Death Dis. 2016 Jun 30;7(6):e2286
pubmed: 27362804
Cancer Immunol Immunother. 2008 May;57(5):647-54
pubmed: 18046553
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562653
Adv Cancer Res. 2018;138:183-211
pubmed: 29551127
Sci Rep. 2016 Mar 04;6:22622
pubmed: 26940009
Genes Dev. 2019 Aug 1;33(15-16):983-1007
pubmed: 31123060
Prog Retin Eye Res. 2020 Mar;75:100800
pubmed: 31563544
Melanoma Manag. 2019 Dec 16;6(4):MMT29
pubmed: 31871618
Br J Ophthalmol. 2017 Jan;101(1):38-44
pubmed: 27574175
Int J Oncol. 2019 Aug;55(2):499-512
pubmed: 31268156
Mol Cancer Res. 2022 Apr 1;20(4):661-669
pubmed: 34992145
Proc Natl Acad Sci U S A. 2022 May 10;119(19):e2107006119
pubmed: 35512098
Clin Cancer Res. 2017 Jul 1;23(13):3307-3315
pubmed: 28053023
Blood Cancer J. 2015 May 15;5:e312
pubmed: 25978432
Cancers (Basel). 2022 Feb 03;14(3):
pubmed: 35159049
Pigment Cell Melanoma Res. 2008 Aug;21(4):457-63
pubmed: 18627530
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671573